Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases

British Journal of Haematology

Volumn 130, Issue 5, 2005, Pages 709-715

  Panteli, Katerina E ^a   Hatzimichael, Eleftheria C ^a,b   Bouranta, Paraskevi K ^a   Katsaraki, Afroditi ^a   Seferiadis, Konstantinos ^a   Stebbing, Justin ^b   Bourantas, Konstantinos L ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Chronic myeloproliferative diseases; Cytokines

Indexed keywords

CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; SOLUBLE INTERLEUKIN 2 RECEPTOR; SOLUBLE INTERLEUKIN 2 RECEPTOR ALPHA; THROMBOPOIETIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CD34 ANTIGEN; INTERLEUKIN 2 RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANGIOGENESIS; ARTICLE; BONE MARROW BIOPSY; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; OVERALL SURVIVAL; PHASE TRANSITION; POLYCYTHEMIA VERA; PREDICTION; PRIORITY JOURNAL; THROMBOTIC THROMBOCYTOPENIC PURPURA; BLOOD; BONE MARROW; BONE MARROW EXAMINATION; CASE CONTROL STUDY; FIBROSIS; METHODOLOGY; MIDDLE AGED; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); NONPARAMETRIC TEST; PATHOLOGY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; BIOLOGICAL MARKERS; BONE MARROW; BONE MARROW EXAMINATION; CASE-CONTROL STUDIES; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROSIS; HUMANS; INTERLEUKIN-1; INTERLEUKIN-2; INTERLEUKIN-6; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, INTERLEUKIN-2; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; THROMBOPOIETIN;

EID: 27244435229     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05674.x     Document Type: Article

References (42)

1. Anand M. Chodda S.K. Parikh P.M. Nadkarni J.S. ( 1998) Abnormal levels of proinflammatory cytokines in serum and monocyte cultures from patients with chronic myeloid leukemia in different stages, and their role in prognosis. Hematological Oncology, 16, 143 154.
2. Araneda M. Krishnan V. Hall K. Kalbfleisch J. Krishnaswamy G. Krishnan K. ( 2001) Reactine and clonal thrombocytosis: proinflammatory and hematopoietic cytokines and acute phase proteins. Southern Medical Journal, 94, 417 420.
3. Barosi G. Ambrosetti A. Finelli C. Grossi A. Leoni P. Liberato N.L. Petti M.C. Pogliani E. Ricetti M. Rupoli S. Visani G. Tura S. ( 1999) The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. British Journal of Haematology, 104, 730 737.
4. Barton B.E. ( 1997) IL-6: insights into novel biological activities. Clinical Immunology and Immunopathology, 85, 16 20.
5. Bourantas K.L. Hatzimichael E.C. Makis A.C. Chaidos A. Kapsali E.D. Tsiara S. Mavridis A. ( 1999) Serum beta-2-microglobulin, TNF-a and interleukins in myeloproliferative disorders. European Journal of Haematology, 63, 19 25.
6. Burstein S.A. ( 1997) Cytokines, platelet production and hemostasis. Platelets, 8, 93 104.
7. Di Raimondo F. Palumbo G.A. Molica S. Giustolisi R. ( 2001) Angiogenesis in chronic myeloproliferative diseases. Acta Haematologica, 106, 177 183.
8. Folkman J. ( 1971) Tumor angiogenesis: therapeutic implications. New England Journal of Medicine, 285, 1182 1186.
9. Griesshammer M. Hornkohl A. Nichol J.L. Hecht T. Raghavachar A. Heimpel H. Schrezenmeier H. ( 1998) High levels of thrombopoietin in sera of patients with essential thrombocythemia: cause or consequence of abnormal platelet production Annals of Hematology, 77, 211 215.
10. Griffin J.D. Rambaldi A. Vallenga E. Young D.C. Ostaporovicz D. Cannistra S.A. ( 1987) Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors. Blood, 70, 1218 1221.
11. Groopman J.E. ( 1980) The pathogenesis of myelofibrosis in myeloproliferative disorders. Annals of Internal Medicine, 92, 857 858.
12. Haznedaroglou I.C. Ertenli H. Ozcebe O.I. Kiraz S. Ozdemir O. Sayinalp N.M. Dundar S.V. Calguneri M. Kirazli S. ( 1996) Megakaryocyte-related interleukines in reactive thrombocytosis versus autonomous thrombocythemia. Acta Haematologica, 95, 107 111.
13. Hollen C.W. Henthorn J. Koziol J.A. Burstein S.A. ( 1991) Elevated serum interleukin-6 levels in patients with reactive thrombocytosis. British Journal of Haematology, 79, 286 290.
14. Hollen C.W. Henthorn J. Koziol J.A. Burstein S.A. ( 1992) Serum interleukin-6 levels in patients with thrombocytosis. Leukemia and Lymphoma, 8, 235 241.
15. Kawatani T. Endo A. Tajima F. Ooi S. Kawasaki H. ( 1997) Clinical significance of serum soluble interleukin-2 receptor in chronic myeloproliferative disorders. Internal Journal of Hematology, 65, 123 128.
16. Korkopoulou P. Viniou N. Kavantzas N. Patsouris E. Thymara I. Pavlopoulos P.M. Terpos E. Stamatopoulos K. Plata E. Anargyrou K. Androulaki A. Davaris P. Yataganas X. ( 2003) Clinicopathologic correlations of bone marrow angiogenesis in chronic myeloid leukemia: a morphometric study. Leukemia, 17, 89 97.
17. Laurent E. Talpaz M. Kantarjian H. Kurzrock R. ( 2001) The BCR gene and Philadelphia chromosome-positive leukemogenesis. Cancer Research, 61, 2343 2355.
18. Long M.W. ( 1999) Thrombopoietin stimulation of hematopoietic stem/progenitors cells. Current Opinions in Hematology, 6, 159 163.
19. Lundberg L.G. Lerner R. Sundelin P. Rogers R. Folkman J. Palmblad J. ( 2000) Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. American Journal of Pathology, 157, 15 19.
20. Mangi H.M. Newland A.C. ( 2000) Angiogenesis and angiogenic mediators in haematological malignancies. British Journal of Haematology, 111, 43 51.
21. Mesa R.A. Hanson C.A. Rajkumar V. Schroeder G. Tefferi A. ( 2000) Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood, 96, 3374 3380.
22. Molica S. Santoro R. Iuliano F. Di Raimondo F. Fichera E. Giustolisi R. ( 2001) Serum levels of vascular endothelial growth factor in chronic leukemias. A comparative study with emphasis on myeloproliferative disorders. Haematologica, 86, 771.
23. Motoi T. Uchiyama T. Hori T. Itoh K. Uchino H. Ueda R. ( 1989) Elevated serum-soluble interleukin-2 receptor (Tac antigen) levels in chronic myelogenous leukemia patients with blastic crisis. Blood, 74, 1052 1057.
24. Murphy S. Peterson P. Iland H. Laszlo J. ( 1997) Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival and leukemic transition by treatment. Seminars in Hematology, 34, 29 39.
25. Musolino C. Calabro L. Bellomo G. Martello F. Loreta B. Pezzano C. Rizzo V. Alonci A. ( 2001) Soluble angiogenic factors: implications for chronic myeloproliferative disorders. American Journal of Hematology, 69, 159 163.
26. Nagler A. Ackerstein A. Barak V. Slavin S. ( 1994) Treatment of chronic myelogenous leukemia with recombinant human interleukin-2 and interferon- alpha 2a. Journal of Hematotherapy, 3, 75 82.
27. Panteli K. Zagorianakou N. Bai M. Katsaraki A. Agnantis N.J. Bourantas K. ( 2004) Angiogenesis in chronic myeloproliferative diseases detected by CD34 expression. European Journal of Haematology, 72, 410 415.
28. Paul C.C. Baumann M.A. ( 1989) Impaired interleukin-2 production by T-lymphocytes in polycythemia vera. Journal of Clinical Laboratory Analysis, 3, 84 87.
29. Pearson T.C. ( 2001) Evaluation of diagnostic criteria in polycythemia vera. Seminars in Haematology, 38, 21 24.
30. Sakai K. Hattori T. Matsuoka M. Asou N. Yamamoto S. Sagawa K. Takatsuki K. ( 1987) Autocrine stimulation of interleukin-1 beta in acute myelogenous leukemia cells. Journal of Experimental Medicine, 166, 1597 1602.
31. Semenzato G. Foa R. Agostini C. Zambello R. Trentin L. Vinante F. Benedetti F. Chilosi M. Pizzolo G. ( 1987) High serum levels of soluble interleukin 2 receptor in patients with B chronic lymphocytic leukemia. Blood, 70, 396 400.
32. Smith K.A. ( 1988) Interleukin-2: inception, impact and implications. Science, 240, 1169 1176.
33. Stebbing J. Benson C. Eisen T. Pyle L. Smalley K. Bridle H. Mak I. Sapunar F. Ahern R. Gore M.E. ( 2001) The treatment of advanced renal cell cancer with high-dose oral thalidomide. British Journal of Cancer, 85, 953 958.
34. Steis R.G. Marcon L. Clark J. Urba W. Longo D.L. Nelson D.L. Maluish A.E. ( 1988) Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia. Blood, 71, 1304 1309.
35. Tahara Y.T. Usuki K. Sato H. Ohashi H. Morita H. Tsumura H. Matsu A. Miyazaki H. Urabe A. Kato T. ( 1996) A sensitive sandwich ELISA for measuring thrombopoietin in human serum: serum thrombopoietin levels in health volunteers and in patients with haemopoietic disorders. British Journal of Haematology, 93, 783 788.
36. Vardiman J.W. Harris N.L. Brunning R.D. ( 2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood, 100, 2292 3002.
37. Vey N. Blaise D. Lafage M. Olive D. Viens P. Baume D. Camerlo J. Stoppa A.M. Gabus R. Brandely M. Hercend T. Maraninchi D. ( 1999) Treatment of chronic myelogenous leukemia with interleukin-2: a phase II study in 21 patients. Journal of Immunotherapy, 22, 175 181.
38. Waldmann T.A. ( 1986) The structure, function and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science, 232, 727 732.
39. Wang J.C. Wang A. ( 1994) Plasma soluble interleukin-2 receptor in patients with primary myelofibrosis. British Journal of Haematology, 86, 380 382.
40. Wang J.C. Chen C. Lou L.-H. Mora M. ( 1997) Blood thrombopoietin, IL-6 and IL-11 levels in patients with agnogenic myeloid metaplasia. Leukemia, 11, 1827 1832.
41. Wetzler M. Kurzrock R. Estrov Z. Kantarjian H. Gisslinger H. Underbrink M.P. Talpaz M. ( 1994) Altered levels of interleukin-1 beta and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates. Blood, 84, 3142 3147.
42. Yamamura M. Yamada Y. Momita S. Kamihira S. Tomonaga M. ( 1998) Circulating interleukin-6 levels are elevated in adult T-cell leukemia/lymphoma patients and correlate with adverse clinical features and survival. British Journal of Haematology, 199, 129 134.